论文部分内容阅读
目的探讨Syndecan-1、bFGF在子宫内膜癌中的表达及临床意义。方法采用免疫组织化学法对50例子宫内膜癌、26例子宫内膜不典型增生及20例正常子宫内膜组织中的Syndecan-1、bFGF进行检测。结果 Syndecan-1、bFGF在子宫内膜癌、子宫内膜不典型增生及正常子宫内膜组织中的强阳性表达率分别为88.89%、88.00%、56.00%和27.78%、32.00%、66.00%,差异有统计学意义(P<0.05)。Syndecan-1的低表达与组织分化、有无肌层浸润、临床分期和有无淋巴结转移有关。bFGF的高表达与组织分化、有无肌层浸润和临床分期有关,与有无淋巴结转移无关。结论 Syndecan-1及bFGF是判断子宫内膜癌预后的重要指标。
Objective To investigate the expression and clinical significance of Syndecan-1 and bFGF in endometrial carcinoma. Methods Fifty cases of endometrial cancer, 26 cases of endometrial dysplasia and 20 cases of normal endometrium were examined for the expression of Syndecan-1 and bFGF by immunohistochemistry. Results The strong positive rates of Syndecan-1 and bFGF in endometrial carcinoma, endometrial dysplasia and normal endometrium were 88.89%, 88.00%, 56.00% and 27.78%, 32.00% and 66.00% respectively, The difference was statistically significant (P <0.05). Syndecan-1 low expression and tissue differentiation, with or without myometrial invasion, clinical stage and with or without lymph node metastasis. High expression of bFGF and tissue differentiation, with or without myometrial invasion and clinical stage, with or without lymph node metastasis. Conclusion Syndecan-1 and bFGF are important prognostic indicators for endometrial cancer.